Deutsches Krebsforschungszentrum

Institut Curie

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

University of London

The Royal Institution for the Advancement of Learning / Mcgill University

Deutsches Krebsforschungszentrum Stiftung Des &ouml;ffentlichen Rechts

Jörg Hoheisel

Manfred Wiessler

Christoph Schröder

Tatjana Crnogorac-Jurcevic

Markus Beier

Peter Lorenz

Heinz Fleischhacker

François Radvanyi

Hans-Christian Kliem

Harish Srinivasan

Pouria Jandaghi

Ole Brandt

Yasser Riazalhosseini

Anette Jacob

Stefan Matysiak

Marc Dauber

The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.

Means and methods for diagnosing pancreatic cancer

The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.

Prediction of recurrence for bladder cancer by a protein signature in tissue samples

The current disclosure relates to methods for treating pancreatic cancer or chronic pancreatitis in a subject comprising administering an antagonist of a dopamine receptor to the subject wherein the dopamine receptor is, in some specific cases dopamine receptor D2 (DRD2). The antagonist in some specific cases is an RNAi construct, an antibody, or a small molecule and in more specific cases pimozide or L-741,626. The disclosure also relates to diagnostic methods comprising the detection of the expression of DRD2 in pancreatic tissue and kits for doing the same.

Pancreatic cancer therapy and diagnosis

The invention relates to a process for the preparation of at least one solid phase bound peptide. PNA or a chimera.

Preparation of solid phase bound peptides or PNAs

The present invention relates to a method for the photolithographic synthesis of biochips in which photolabile protective groups of the 2-(2-nitrophenyl)ethyl type are used, whereby the irradiation step that is common in the photolithographic chip synthesis is carried out in the presence of a base, preferably a secondary or uerriary base.

Method for the light-controlled synthesis of biochips

Growing community of inventors

Wiesloch, Germany

Jörg Hoheisel